ABBOTT LABORATORIES — Regulatory Filings 2011

Jan 13, 2011

8-K 1 a11-1977_18k.htm 8-K

*UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549*

*FORM 8-K*

*CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934*

*January 7, 2011*

Date of Report (Date of earliest event reported)

*ABBOTT LABORATORIES*

(Exact name of registrant as specified in its charter)

Illinois (State or other Jurisdiction of Incorporation) 1-2189 (Commission File Number) 36-0698440 (I.R.S. Employer Identification No.)

*100 Abbott Park Road Abbott Park, Illinois 60064-6400*

(Address of principal executive offices)(Zip Code)

Registrant’s telephone number, including area code: (847) 937-6100

Check the appropriate box if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

SEQ.=1,FOLIO='',FILE='C:\JMS\105536\11-1977-1\task4426730\1977-1-ba.htm',USER='105536',CD='Jan 13 03:19 2011'

*Item 5.02 — Departure of Directors or Certain Officers*

In connection with his appointment as Chief of Staff to President Obama, William M. Daley has resigned from the Board of Directors of Abbott Laboratories, effective January 7, 2011.

*Item 5.03 — Amendment to Articles of Incorporation or Bylaws*

On January 7, 2011, Abbott Laboratories’ Board of Directors amended the first sentence of Article III, Section 2 of Abbott’s by-laws to provide that Abbott’s Board of Directors shall consist of thirteen persons. Abbott’s by-laws previously provided that the Board of Directors consisted of fourteen persons.

*Item 9.01 — Financial Statements and Exhibits*

(d) Exhibits

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective January 7, 2011

2

SEQ.=1,FOLIO='2',FILE='C:\JMS\105536\11-1977-1\task4426730\1977-1-ba.htm',USER='105536',CD='Jan 13 03:19 2011'

*Signatures*

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 13, 2011
By:	/s/ Thomas C. Freyman
	Thomas C. Freyman
	Executive Vice President,
	Finance and Chief Financial Officer

3

SEQ.=1,FOLIO='3',FILE='C:\JMS\105536\11-1977-1\task4426730\1977-1-ba.htm',USER='105536',CD='Jan 13 03:19 2011'

*Exhibit Index*

Exhibit No.	Exhibit
3.1	By-Laws of Abbott Laboratories, as amended and restated effective January 7, 2011

4

SEQ.=1,FOLIO='4',FILE='C:\JMS\105536\11-1977-1\task4426730\1977-1-ba.htm',USER='105536',CD='Jan 13 03:19 2011'